M.D., Chairman and CSO, Xyphos, Inc.
David attended MIT, received his MD and clinical training at Duke, was a post-doctoral fellow at NIH. Joined the faculty at UCSF in the Departments of Medicine and Biochemistry where he became professor in both and Investigator of the Howard Hughes Medical Institute. He joined Genentech in 1982 as its first VP of R&D. In 1991 he joined DuPont-Merck as Executive VP of R&D and later returned to the Bay Area as president of Chiron Therapeutics. He co-founded Eos Biotechnologies and AvidBiotics. He served on the boards of Millennium BioTherapeutics, Cubist Pharmaceuticals, Varian Associates, Varian Medical Systems, BayBio, and now ICOC of CIRM. He and his family live in Marin County.
Presentation Title and Company Description
Immunotherapy Showcase: MicAbody™-controlled Activation and Targeting of convertibleCAR™-T Cells
Xyphos Inc., a preclinical company in South San Francisco, was recently formed from AvidBiotics to develop convertibleCAR™-T cell products based on its immuno-oncology platform and IP assets. Xyphos’ product candidates enhance safety, flexibility and versatility of CAR-Ts while retaining efficacy.